The FDA released draft guidelines to support pharmaceutical companies in developing non-opioid medications for chronic pain management, promoting broader indications and clinical trial strategies addressing diverse pain conditions. The agency emphasizes the difficulty of accelerated approval pathways due to pain’s subjective nature but signals openness to expedite options. This regulatory encouragement aims to spur innovation toward alternatives to opioids, addressing the ongoing opioid crisis by offering physicians more effective and safer treatments.